Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioMarin Pharmaceutical

Explore full profile

Developing innovative therapies targeting rare genetic diseases

San Rafael, United StatesFounded 1997Biotech & Life Sciences
Valuation $11B Market cap · Aug/2026
Revenue $3.87B Latest reported FY
EBITDA $573M Latest reported FY

At a glance

Status
Listed
Founded
1997
Headquarters
San Rafael, United States
Listing
IPO 1999
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
News
News BioMarin to acquire Alesta for $275M upfront to gain oral rare-disease drug Aug 18, 2026

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Clubb Capital
  • BBB
  • Genzyme

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 10 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Alumni founders

5 of 10 startups shown

Former BioMarin Pharmaceutical employees who went on to found companies, sorted by Dealroom signal score.

One BiosciencesEst. 2020
MRMagali RichardFrance
Signal score92
Janux TherapeuticsEst. 2017
Tommy DiRaimondoUnited States
Signal score87
MendraEst. 2025
JGJoshua GrassUnited States
Signal score86
GlycomineEst. 2013
Agnes RafalkoUnited States
Signal score83
Audentes TherapeuticsEst. 2013
Matthew PattersonUnited States
Signal score68
5 more alumni-founded companies in this previewBook a demo

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Rafael HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$457M

218 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where BioMarin Pharmaceutical was the backer or acquirer, 2010–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across BioMarin Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        BioMarin Pharmaceutical's portfolio, mapped.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about BioMarin Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioMarin Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles